Circulating monocytoid cells have the ability to infiltrate nervous tissue, differentiate into microglia, and clear amyloid-␤ (A␤) from the brain of mouse models of Alzheimer's disease. Interaction between the chemokine CCL2 and its CC chemokine receptor 2 (CCR2) plays a critical role in the recruitment of inflammatory monocytes into the injured/diseased brain. Here, we show that CCR2 deficiency aggravates mnesic deficits and amyloid pathology in transgenic mice expressing the chimeric mouse/human ␤-amyloid precursor protein and presenilin 1 (APP Swe /PS1). Indeed, memory impairment was accelerated and enhanced in APP Swe /PS1/CCR2 Ϫ/Ϫ mice. Apparition of cognitive decline occurred earlier (i.e., at 3 months of age before plaque formation) and correlated with intracellular accumulation of soluble oligomeric forms of A␤. Memory deficits worsened with age and were aggravated in APP Swe /PS1/CCR2 Ϫ/Ϫ mice compared with their respective control groups. Soluble A␤ assemblies increased significantly in APP Swe /PS1 mice in a context of CCR2 deficiency, whereas the plaque load remained relatively similar in the brain of aging APP Swe /PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice. However, CCR2 deficiency stimulated the expression of TGF-␤1, TGF-␤ receptors, and CX 3 CR1 transcripts in plaque-associated microglia, a pattern that is characteristic of an antiinflammatory subset of myeloid cells. A decreased expression of CCR2 could play a potential role in the etiology of Alzheimer's disease, a neurodegenerative pathology that could be treated by a genetic upregulation of the transgene in monocytoid cells.
Introduction
Alzheimer's disease (AD), the most common cause of dementia in the elderly, is characterized by a progressive decline in memory. The pathological hallmarks of AD are senile plaques, intracellular neurofibrillary tangles, accumulation of activated microglia and astrocytes around ␤-amyloid (A␤) plaques, and degenerative neurons (Selkoe, 2002) . The A␤ peptide is produced by amyloid precursor protein (APP) cleavage, and two main A␤ isoforms exist (i.e., A␤ and A␤ 1-42 ). A␤ can form different oligomeric assemblies, such as monomers, dimers, or A␤*56, to finally generate amyloid plaques (Lesné et al., 2006; Haass and Selkoe, 2007) . These senile plaques contain densely packed A␤ fibrils and a large number of molecules and cellular elements. In particular, microglia, the mononuclear phagocytes of the brain (Perry and Gordon, 1988) , are attracted around amyloid plaques and originate in part from the periphery (Malm et al., 2005; Stalder et al., 2005; Simard et al., 2006) .
Monocytes constitutively express several chemokine receptors, which induce leukocyte migration and attraction by binding to their specific chemotactic cytokines, or chemokines (Luster, 1998; Charo and Ransohoff, 2006; Auffray et al., 2009) . CC chemokine receptor 2 (CCR2) is mainly expressed on the surface of monocytes (Mack et al., 2001) . In mice, two principal subsets of monocytes are defined by CCR2 expression, CX 3 CR1 lo CCR2 ϩ
GR1
ϩ inflammatory and CX 3 CR1 hi CCR2 Ϫ
Ϫ resident monocytes (Geissmann et al., 2003) . CCR2 is involved in the brain infiltration of monocytes in a mouse model for multiple sclerosis (Izikson et al., 2000) , at sites of axonal injury in the hippocampus (Babcock et al., 2003) and in systemic organs during inflammation (D'Mello et al., 2009 ). The main CCR2 chemokine ligand is monocyte chemotactic protein-1 (MCP-1) [CCL2 (CC chemokine ligand 2)] and is expressed in many cells, including endothelial cells (Cushing et al., 1990; Rollins et al., 1990) , astrocytes (Glabinski et al., 1996; Smits et al., 2002) , and microglia (Meda et al., 1995; El Khoury et al., 2003; Deshmane et al., 2009) .
MCP-1 is upregulated in the brain of AD patients in mature senile plaques, microglia (Ishizuka et al., 1997) , and microvessels (Grammas and Ovase, 2001) . MCP-1 expression is also increased in the brain of AD transgenic mice (Simard et al., 2006; El Khoury et al., 2007) and A␤ stimulates MCP-1 production in cultures of microglia (Meda et al., 1995; El Khoury et al., 2003) and astrocytes (Smits et al., 2002) . Together, these data strongly suggest a predominant role of CCR2 in AD, since CCR2 is the key signaling receptor for MCP-1 (Deshmane et al., 2009 ). This was recently evidenced by a study using APP Tg2576 mice, a mouse model of AD developing the hallmarks of the disease tardily (9 -10 months of age) (Hsiao et al., 1996) . Unfortunately, their breeding with CCR2 Ϫ/Ϫ mice produced APP-CCR2 Ϫ/Ϫ mice dying prematurely (i.e., before A␤ plaque formation or microglia recruitment around A␤ deposits) (El Khoury et al., 2007) , severely limiting the in vivo study of disease development. To overcome this limitation, we used another APP transgenic mouse model, the APP Swe /PS1 mice, a well established model of AD (Borchelt et al., 1997; Simard et al., 2006; Richard et al., 2008; Boissonneault et al., 2009) .
The main objective of this study was to follow progression of the disease in a context of CCR2 gene deficiency. All our results converge into a very important beneficial role of CCR2-expressing cells in AD.
Materials and Methods
Transgenic mice. We used adult male C57BL/6 mice [wild type (WT)], CCR2 Ϫ/Ϫ (B6.129S4-Ccr2tm1Ifc/J), and APP transgenic mice (APP Swe / PS1) harboring the chimeric mouse/human ␤-amyloid precursor protein (APP695swe) and the human presenilin I (A246E variant) under the control of independent mouse prion protein promoter elements [B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J]. APP Swe /PS1 were bred with the CCR2 Ϫ/Ϫ mouse strain for three or more generations to generate APP Swe /PS1/CCR2 Ϫ/Ϫ triple transgenic animals. All mouse strains were purchased from The Jackson Laboratory and maintained in a C57BL/6J background. All newborn pups were genotyped as described in The Jackson Laboratory protocol. A total of 201 mice were used to study behavioral and biochemical modifications from 3 to 12 months of age. Mice were housed at three to five per cage and acclimated to standard laboratory conditions (12 h light/dark cycle; lights on at 7:00 A.M. and off at 7:00 P.M.) with ad libitum access to mouse chow and water. Animal breeding and experiments were conducted according to Canadian Council on Animal Care guidelines, as managed by the Laval University Animal Care Committee.
Water T-maze. Mice were tested during the "lights-on" phase of the day. The behavioral experimenter was blinded to the genetic and treatment status of the animals. To assess hippocampal-dependent spatial learning and memory, mice were trained in the water T-maze task. In this paradigm, we evaluate the mouse's ability to remember the spatial location of a submerged platform. The T-maze apparatus (length of stem, 64 cm; length of arms, 30 cm; width, 12 cm; height of walls, 16 cm) was made of clear fiberglass and filled with water (23 Ϯ 1°C) at a height of 12 cm. A platform (11 ϫ 11 cm) was placed at the end of the target arm and was submerged 1 cm below the surface. The acquisition phase allows to evaluate animals for left-right spatial learning. During the first two trials, platforms were placed on each arms of the maze to test the spontaneous turning preference of the mouse. After these two trials, the least chosen arm was reinforced by the escape platform. The mice were placed in the stem of the T-maze and chose to swim either left or right until they found the submerged platform and escaped to it, to a maximum of 60 s. After reaching the platform, the mice remained on it for 20 s and then were immediately put back in the maze. If the animals did not find the platform within this time limit, they were gently guided onto it. Repeated trials were presented on the same day up to a maximum of 48 trials. A rest period of at least 10 -15 min was allowed between each block of 10 trials. A mouse was considered to have learned the task when it made no errors in a block of five consecutive trials. The reversal learning phase was then conducted 48 h later. During this phase, the same protocol was repeated, except that the mice were trained to find the escape platform on the side opposite to that on which they had learned during the acquisition phase. The number of trials needed to reach the criterion (five of five correct choices made on consecutive trials) was noted as well as the latency for finding the escape platform.
Passive avoidance test. Based on the animal's natural tendency to prefer the dark environment, mice were also evaluated on their retention of nonspatial memory for one-trial passive avoidance task. The passive avoidance apparatus (Ugo Basile) was divided into two sections, one illuminated (start compartment) and the other dark (escape compartment). The floor of each compartment contained a grid, with only the dark compartment being electrified by a generator. On the training day, mice were placed into the lighted (start) compartment for a 60 s acclimation period. The guillotine door was then opened, and the latency to enter the dark side was recorded. Immediately after entering the dark compartment, the door was closed and an electric shock (0.5 mA for 2 s) was delivered. The mouse was kept in the dark compartment for 10 s before being returned to its home cage. On the next day, the mice were again placed in the lighted compartment, and the step-through latency time to enter the dark side was measured for up to 300 s.
Tissue analyses. Transgenic mice were anesthetized under isoflurane and blood was drawn via cardiac puncture before decapitation. Brains were rapidly removed from the skulls and placed in cold PBS solution. Then hemibrains were separated and olfactory bulbs and cerebellum were removed. One hemibrain was rapidly frozen in liquid nitrogen and stored at Ϫ80°C for protein analysis. The other one was postfixed for 2-4 d in 4% paraformaldehyde, pH 9.5, at 4°C, and then placed in a paraformaldehyde solution containing 10% sucrose overnight at 4°C. The frozen brains were mounted on a microtome (Reichert-Jung) and cut into 25 m coronal sections. The slices were collected in cold cryoprotectant solution (0.05 M sodium phosphate buffer, pH 7.3, 30% ethylene glycol, and 20% glycerol) and stored at Ϫ20°C until immunocytochemistry or in situ hybridization histochemistry.
In situ hybridization and immunohistochemistry. Every 12th section of brain slices, starting from the end of the olfactory bulb to the end of the cerebral cortex, was mounted on Colorfrost/Plus microscope slides (Thermo Fisher Scientific) for APP Swe /PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice (3-12 months of age; n ϭ 5-12 per group). Histochemical localization of CX 3 CR1, TGF-␤1, and TGF-␤ receptors R1 and R2 by in situ hybridization was performed using 35 S-labeled cRNA probes. Plasmids were linearized, and sense and antisense cRNA probes were synthesized with the appropriate RNA polymerase, as described in Table 1 . Riboprobe synthesis and preparation, as well as in situ hybridization were performed according to a protocol described previously (Laflamme et al., 1999; Nadeau and Rivest, 2000; Laflamme and Rivest, 2001; Naert et al., 2009) .
Dual labeling combining immunocytochemistry and in situ hybridization was performed as described previously (Nadeau and Rivest, 2000; Laflamme and Rivest, 2001 ) to detect CX 3 CR1, TGF-␤1, TGF-␤ R1, and TGF-␤ R2 transcripts in microglia (iba-1 ϩ -staining). We used polyclonal rabbit anti-ionized calcium binding adaptor molecule 1 (iba-1) (1:3000; Wako Chemicals).
The expression level of each transcript was estimated by qualitative analysis using a Nikon Eclipse 80i microscope over the whole-brain sections for 5-10 animals/group. Quantitative analysis of hybridization signal for CX 3 CR1 mRNA was performed on images captured using a Nikon Eclipse 80i microscope equipped with a digital camera (QImaging) and the ImageJ software. Three coronal sections were chosen for prefrontal cortex at ϩ2.58, ϩ2.34, and ϩ2.10 mm from the bregma according to a stereotaxic atlas (Paxinos and Franklin, 2001 ) and four All images were captured using a Nikon Eclipse 80i microscope equipped with a digital camera (QImaging), processed to enhance contrast and sharpness using Adobe Photoshop 7 (Adobe Systems), and then assembled using Adobe Illustrator (Adobe Systems). The images depicted by the different panels are representative of the signal detected on the slides for each group of mice.
Stereological analysis. An observer who was blind to the treatment status of the material did all quantitative histological analyses. To count A␤ plaques and plaque-associated microglia, sections of APP Swe /PS1 and APP Swe /PS1/ CCR2 Ϫ/Ϫ mice (3-12 months of age, n ϭ 7-15 per group) were immunostained for A␤ (polyclonal mouse anti-A␤ 6E10; 1:3000; Covance) and iba-1 proteins with DAPI (4Ј,6Ј-diamidino-2-phenylindole), as previously reported (Simard et al., 2006; Richard et al., 2008) . Two sections were chosen for prefrontal cortex at ϩ2.34 and ϩ2.10 mm from the bregma according to a stereotaxic atlas (Paxinos and Franklin, 2001 ) and four sections for hippocampus/cerebral cortex at Ϫ1.70, Ϫ1.94, Ϫ2.46, and Ϫ2.92 mm. Unbiased stereological analysis was performed as described previously (Simard et al., 2006; Richard et al., 2008; Boissonneault et al., 2009) . Briefly, the contours of the prefrontal cortex, the hippocampus, and the cortex areas were traced as virtual overlay on the streamed images and areas were calculated. For 3-and 6-month-old APP Swe /PS1 mice, the area occupied by all A␤-labeled plaques was determined as well as the number of plaque-associated microglia in each structure. For 9-and 12-month-old APP Swe / PS1 mice, the Stereo Investigator software (MicroBrightField) sequentially chose counting frames (670 ϫ 500 mm) at every 2000 m along the x-axis and every 1000 m along the y-axis while automatically moving the motorized stage into the previously delimited zones in the prefrontal cortex, the hippocampus, and the cortex. The areas of analyzed structures and areas occupied by plaques were calculated, as well as the number of plaque-associated microglia in these counting frames. All parameters analyzed were reported to the whole section.
Protein extraction and detection of total A␤ levels by Western blot. Proteins from hemi-forebrains were extracted using a modification of the procedure described by Lesné et al. (2006) . All manipulations were done on ice to minimize protein degradation. One hemi-forebrain was placed in a 1 ml syringe with a 20 G needle. Five hundred microliters of buffer A [50 mM Tris-HCl, pH 7.6, 0.01% NP-40, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride (PMSF), protease inhibitor mixture] were added and 10 up-and-down passages were made to homogenize the tissue, followed by a 5 min centrifugation at 3000 rpm at 4°C. The supernatant (extracellular protein-enriched fraction) was then collected and frozen at Ϫ80°C. The insoluble pellet was suspended in 500 l of TNT buffer (buffer B; 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Triton X-100, 1 mM PMSF, protease inhibitor mixture), followed by a 90 min centrifugation at 13,000 rpm at 4°C. The supernatant (cytoplasmic protein-enriched fraction) was then collected and frozen at Ϫ80°C. The pellet was suspended in 500 l of buffer C (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM EGTA, 3% SDS, 1% deoxycholate, 1 mM PMSF, protease inhibitor mixture) and incubated at 4°C, 50 rpm for 1 h. The samples were centrifuged for 90 min at 13,000 rpm and 4°C, and the supernatant (membrane protein-enriched fraction) was collected and frozen at Ϫ80°C. The protein concentration in each fraction was determined using the Quantipro bicinchoninic acid assay kit (SigmaAldrich) according to the manufacturer's protocol.
For total A␤ detection, 10 -30 g of extracellular, cytoplasmic, and membrane protein fractions were separated on a precast 10 -20% SDS polyacrylamide Tris-Tricine gel (Bio-Rad). Separated proteins were then transferred onto polyvinylidene fluoride membranes (PerkinElmer Life and Analytical Sciences) and detected by Western blotting. Blots were probed with a mouse anti-A␤ protein monoclonal antibody clone 6E10 (1:1000; Covance) in a buffer containing 1 M Tris-HCl, pH 8.0, 5 M NaCl, 5% skim milk, and 0.05% Tween 20. Blots were visualized using an anti-mouse secondary antibody tagged with horseradish peroxidase (1: 1000; Jackson ImmunoResearch) and enhanced chemiluminescence (PerkinElmer Life and Analytical Sciences). Membranes were stripped in 25 mM glycine-HCl, pH 2.0, containing 1% SDS to detect ␤-actin using first a mouse ␤-actin antibody (MAB1501; 1:5000; Millipore Bioscience Research Reagents) and then a goat anti-mouse peroxidase-conjugated secondary antibody (1:1000; Jackson ImmunoResearch). Ϫ/Ϫ mice exhibited an earlier and greater spatial memory decline than APP Swe /PS1 mice. The passive avoidance test was used to establish contextual memory deficit (e, f ). The latency was determined at 3-12 months of age during the acquisition phase (e) and 24 h after the conditioning test (f ) for each group. The latency to enter the dark compartment was already decreased at 6 months of age in APP Swe /PS1/ CCR2 Ϫ/Ϫ mice compared with the control groups of mice. Results are expressed as mean Ϯ SEM; n ϭ 8 -16 per group; *p Ͻ 0.05, **p Ͻ 0.01, and ***p Ͻ 0.001. *Versus WT at same age;°versus CCR2 Ϫ/Ϫ at same age; # versus APP Swe /PS1 at same age. (Two-way ANOVA was performed and, for each parameter analysis, revealed a significant interaction between the factors of age and genotype. Then, one-way ANOVA at each level of age was performed using Bonferroni's or Tamhane's post hoc test.)
Quantification was done by determining integrated density of the bands using a gel imaging system (scanner Agfa Arcus II; NIH ImageJ software, version 1.32j), and background values were subtracted. Optical values were normalized relatively to the actin loading control. Results are expressed as mean Ϯ SEM.
Statistical analysis. Results are expressed as mean Ϯ SEM. Statistical analysis was performed by one-or two-way ANOVA, followed by either Bonferroni's or Thamane's tests as appropriate, as post hoc comparisons (SPSS software). Data were analyzed using standard two-tailed unpaired t test for comparisons between two groups. Correlations were estimated by linear regression analysis and the Spearman's correlation coefficient (GraphPad Software) with p and r values and 95% confidence intervals included in the graph. A value of p Ͻ 0.05 was considered statistically significant. Ϫ/Ϫ mice. Brain sections of 3-to 12-month-old APP Swe /PS1 (a-d) and APP Swe /PS1/CCR2 Ϫ/Ϫ mice (e-h) were immunostained for A␤. Unbiased stereological analysis of plaques was performed in hippocampus to determine plaque density (i-l ), plaque size (m-p), and the area percentage occupied by plaques (q-t) of 3-to 12-month-old APP Swe /PS1 (open bar) and APP Swe /PS1/CCR2 Ϫ/Ϫ mice (solid bar). APP Swe /PS1/CCR2 Ϫ/Ϫ and APP Swe /PS1 mice had similar amyloid plaque formation at 3, 6, and 9 months of age. However, a significant higher A␤ load was found in the hippocampus of 12-month-old APP Swe /PS1/CCR2 Ϫ/Ϫ mice. Results are expressed as mean Ϯ SEM; n ϭ 7-15 per group; Student's t test; *p Ͻ 0.05 and **p Ͻ 0.01 versus APP Swe /PS1 at same age. Scale bar, 500 m.
Results

CCR2 deficiency aggravates cognitive impairment in APP Swe /PS1 mice
To determine whether CCR2 deficiency affects disease progression, we bred APP Swe /PS1 mice with CCR2-deficient animals. APP Swe /PS1/CCR2 Ϫ/Ϫ mice appeared healthy and had a survival curve comparable with APP Swe /PS1 mice, reaching Ͼ12 months of age (Fig. 1) . Mice of each genotype from 3 to 12 months of age were submitted to hippocampus-based spatial learning in a water T-maze (Fig. 1a-d) and displayed similar swimming capacity and motivation to escape from water. During this acquisition phase, the means of trials (Fig. 1a) and the latency (Fig. 1c) to reach the criterion were similar between mice independently of genotype and age. During the reversal phase, 3-to 12-month-old WT and CCR2 Ϫ/Ϫ mice were able to learn the novel platform location. APP Swe /PS1 mice exhibited memory impairment starting at 6 months of age and this deficit worsened with age (Fig. 1b,d ). The spatial memory was affected earlier and to a greater extent in APP Swe /PS1/CCR2 Ϫ/Ϫ mice, which exhibited a significant increase in the number of trials made (14.2 Ϯ 1.8 vs 4.6 Ϯ 1.1 for APP Swe /PS1; p Ͻ 0.001) starting at 3 months of age, and the time spent to reach the platform (15.7 Ϯ 1.4 vs 11.3 Ϯ 0.7 for APP Swe / PS1; p Ͻ 0.05). The larger decline of spatial memory seen in APP Swe /PS1/CCR2 Ϫ/Ϫ mice progressed gradually with age, as evidenced by the number of trials at 6 and 9 months of age (22.9 Ϯ 2.4 vs 14.5 Ϯ 1.6 for APP Swe /PS1; p Ͻ 0.05 and 26.9 Ϯ 3.1 vs 16.8 Ϯ 1.5 for APP Swe /PS1; p Ͻ 0.05, respectively) and by the increased latency at 6 months (18.5 Ϯ 1.8 vs 13.0 Ϯ 0.5 for APP Swe /PS1; p Ͻ 0.05). At 12 months of age, no difference in spatial memory was shown with the water T-maze task, suggesting that memory impairment had reached a plateau at that age in both groups of APP Swe /PS1 mice.
To assess contextual memory, mice were submitted to the passive avoidance test. All animals were trained to avoid a dark compartment and presented similar latency to enter the dark side from 3 to 12 months of age during the acquisition phase (Fig. 1e) . Twenty-four hours after the conditioning test, both APP Swe /PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice exhibited a decreased latency, although it appeared earlier in APP Swe /PS1/CCR2 Ϫ/Ϫ mice (Fig.  1f ) . At 6 months, a significantly decreased latency was observed only in APP Swe /PS1/CCR2 Ϫ/Ϫ mice (103 Ϯ 15 vs 239 Ϯ 26 for WT; p Ͻ 0.001). This contextual memory impairment reached a significant level at 9 months in APP Swe /PS1 mice (107 Ϯ 20 vs 283 Ϯ 9 for WT; p Ͻ 0.001). This cognitive decline was maintained with age and was similar at 9 and 12 months between the two groups of APP Swe /PS1 mice.
These results demonstrate a greater cognitive impairment in APP Swe /PS1/CCR2 Ϫ/Ϫ mice, which appeared earlier than in APP Swe /PS1 mice, suggesting that CCR2 deficiency has deleterious effects on memory and learning processes.
CCR2 deficiency increases levels of soluble A␤ oligomers without changing A␤ deposition
The major hallmark of AD is A␤ accumulation in brain, which correlates strongly with mnesic impairment (Selkoe, 2002) . We first quantified the plaque load by stereological analyses on coronal sections stained with the 6E10 antibody specific for the 1-17 fragment of the human A␤ protein. Similar A␤ plaque burden was found in APP Swe /PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice from 3 to 9 months of age in hippocampus (Fig. 2) , prefrontal cortex (Fig. 3, left column) , and cerebral cortex (Fig. 3, right column) . Plaque number, plaque size, and area occupied by A␤ plaques increased with age in both groups. At 12 months of age, the area occupied by plaques in prefrontal cortex (Fig. 3i ) and hippocampus (Fig. 2t) was larger in APP Swe /PS1/CCR2 Ϫ/Ϫ mice (2.67 Ϯ 0.22%, p Ͻ 0.05, and 1.24 Ϯ 0.17%, p Ͻ 0.001, respectively) than APP Swe /PS1 littermates (1.87 Ϯ 0.21 and 0.57 Ϯ 0.12%, respectively).
These results do not support a significant correlation between plaque formation and the occurrence of cognitive impairment in a context of CCR2 deficiency. It is important to mention that the severity of dementia in AD patients correlates more strongly with cortical levels of soluble A␤ species than with insoluble A␤ plaque burden (Lue et al., 1999; McLean et al., 1999) . Moreover, memory deficits also correlate with soluble A␤ oligomers instead of A␤ plaque in mouse models of AD (Lesné et al., 2006; Cheng et al., 2007) . Therefore, we next determined levels of soluble A␤ in the extracellular-and intracellular-enriched, and membraneassociated protein fractions by Western blot, using the method published by Lesné et al. (2006) . Ϫ/Ϫ mice. Anti-A␤ immunoreactivity is depicted in the prefrontal cortex (left column) and cerebral cortex (right column) of APP Swe /PS1 (a, b) and APP Swe /PS1/ CCR2 Ϫ/Ϫ mice (c, d) at 9 months of age. A detailed analysis of plaque quantification was performed to determine plaque density (e, f ), plaque size (g, h), and the area percentage occupied by plaques (i, j) of 3-to 12-month-old APP Swe /PS1 (open bar) and APP Swe /PS1/ CCR2 Ϫ/Ϫ mice (solid bar). Amyloid plaque formation was similar in both groups at 3, 6, and 9 months of age, although A␤ plaque load significantly increased in the prefrontal cortex of 12-month-old APP Swe /PS1/CCR2 Ϫ/Ϫ mice. Results are expressed as mean Ϯ SEM; n ϭ 7-15; Student's t test; *p Ͻ 0.05 vs APP Swe /PS1 at the same age. Scale bar, 500 m.
At 3 months of age, similar levels of A␤ species were observed in extracellularenriched and membrane-associated protein fractions between APP Swe /PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice ( Fig. 4a,b ; e,f, respectively). By contrast, APP Swe /PS1/ CCR2 Ϫ/Ϫ mice exhibited increased levels of A␤ species in the intracellular-enriched fraction comparatively to APP Swe /PS1 mice (Fig. 4c,d ). To establish whether these higher levels of intracellular A␤ species contribute to the appearance of mnesic deficit, we determined the correlation between spatial memory decline (water T-maze test) and soluble intracellular A␤ (Fig. 4g-m) . We noted a significant positive correlation between the levels of most A␤ species and impairment of spatial memory, with a better correlation for high-molecular-mass assemblies ( Fig. 4g-j) .
Although A␤ levels in extracellularenriched and membrane-associated fractions remained comparable in 6-month-old APP Swe /PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice ( Fig. 5a,b ; e,f, respectively), higher intracellular trimer A␤ levels were found in the brain of APP Swe /PS1/CCR2 Ϫ/Ϫ (Fig.  5c,d ). At 9 months of age, levels of soluble A␤ species were significantly increased in extracellular-, intracellular-enriched, and membrane-associated protein fractions of APP Swe /PS1/CCR2 Ϫ/Ϫ (Fig. 5 ). These changes in extracellular and intracellular soluble A␤ vanished at 12 months of age, but APP Swe /PS1/CCR2 Ϫ/Ϫ brains still had significantly higher 9-, 6-, and 5-mer levels in membrane-associated fractions (Fig. 5f ).
These data provide evidence that levels of soluble A␤ oligomers in extracellular-, intracellular-enriched, and membraneassociated fractions increased in the brains of APP Swe /PS1/CCR2 Ϫ/Ϫ mice and intracellular A␤ correlated strongly with early cognitive deficits in a context of CCR2 deficiency.
Enhanced microglial expression of TGF-␤1 and TGF-␤ receptors in APP Swe /PS1/CCR2
؊/؊ mice In addition to A␤ production and accumulation, microglia are attracted to amyloid deposits, are activated by A␤, and express inflammatory molecules. In particular, TGF-␤1, a pleiotropic cytokine with a central role in immune suppression (Li et al., 2006) , was shown to contribute to A␤ deposition in a transgenic mouse model of AD (Wyss-Coray et al., 1997) . We found a robust signal for TGF-␤1 and its receptors from 6 to 12 months of age in APP Swe /PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice (Fig. 6) . The signal was mainly associated to senile plaques in prefrontal cortex, hippocampus, and cerebral cortex and all mRNAs are expressed in iba1-positive microglial cells (Fig.  6c,f,i) . Qualitative analysis demonstrated an increase in the number of positive cells and the signal intensity for TGF-␤1 and TGF-␤-R2 mRNA in APP Swe /PS1/CCR2 Ϫ/Ϫ mice, whereas TGF-␤-R1 mRNA levels were lower in 9-and 12-month-old APP Swe /PS1/ CCR2 Ϫ/Ϫ mice (Fig. 6j) .
Enhanced recruitment of CX 3 CR1 microglia surrounding A␤ plaques in APP Swe /PS1/CCR2 ؊/؊ mice Stereological analyses were performed on coronal brain sections immunostained for iba1 and A␤ to count plaque-associated microglia. At 3 months of age, APP Swe / PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice had a similar number of microglia around the few A␤ plaques (Fig. 7f-h) . Microglia recruitment in the plaque vicinity reached a plateau at 6 months in APP Swe /PS1 and APP Swe /PS1/CCR2 Ϫ/Ϫ mice and more plaque-associated microglia were found in the cortex of APP Swe /PS1/CCR2 Ϫ/Ϫ mice (0.0045 Ϯ 0.0002 vs 0.0019 Ϯ 0.0002 microglia/m 2 for APP Swe /PS1; p Ͻ 0.05) (Fig. 7h) . This enhanced recruitment of microglia became more pronounced in 9-month-old APP Swe /PS1/CCR2 Ϫ/Ϫ mice and was significantly different from APP Swe /PS1 mice for the prefrontal cortex (Fig. 7f-h) . At 12 months of age, both groups of mice exhibited a similar recruitment in all regions studied. This increased recruitment was concomitantly observed with an enhanced expression of MCP-1. In fact, in situ hybridization was performed for MCP-1 mRNA (Fig. 7a-d) and showed a strong increase of MCP-1 signal in APP Swe /PS1/CCR2 Ϫ/Ϫ mice from 3 to 12 months of age (Fig. 7e) . In APP Swe /PS1 mice, MCP-1 expression was induced later at 6 months and also increased with age (Fig. 7e) . In addition, this increased recruitment correlated with a strong expression of CX 3 CR1 mRNA in microglia (Fig. 8) . Although the transcript was constitutively expressed in microglia in both groups of mice, APP Swe /PS1/CCR2 Ϫ/Ϫ mice exhibited higher CX 3 CR1 mRNA levels than APP Swe /PS1 mice in the prefrontal cortex (data not shown) and cerebral cortex at 9 months of age (1.15 Ϯ 0.10 vs 0.65 Ϯ 0.17% in APP Swe /PS1; p Ͻ 0.05) (Fig. 8f ) .
We have shown that, surprisingly, microglia recruitment in and around senile plaque is increased, strongly suggesting that a compensatory process takes place in the brain to counteract CCR2 deficiency.
Discussion
Our data offer new insight on the importance and role of microglia in the etiology of AD. We demonstrate that CCR2 deficiency in a mouse model of AD accelerated the onset of disease and aggravated mnesic deficits and A␤ pathology. AD brain contains soluble and insoluble assemblies of A␤, both of which have been hypothesized to underlie dementia. However, the correlation between parenchymal amyloid deposi- Ϫ/Ϫ mice. Hemibrain extracts from soluble extracellular (a), intracellular (c), and membrane-associated proteins (e) of 6-to 12-month-old APP Swe /PS1 (A) and APP Swe /PS1/CCR2 Ϫ/Ϫ (AC) mice were assessed by Western blot. The intensity of each band was quantified by densitometric analysis and normalized per ␤-actin values. A␤ species ratios (A␤/␤-actin) are represented for extracellular (b), intracellular (d), and membrane-associated proteins (f). Soluble A␤ species levels were generally higher in the brains of APP Swe /PS1/CCR2 Ϫ/Ϫ mice than those of APP Swe /PS1 mice. Results are expressed as mean Ϯ SEM; n ϭ 4 -5; Student's t test; *p Ͻ 0.05, **p Ͻ 0.01, and ***p Ͻ 0.001. *Versus APP Swe /PS1 at the same age. tion and cognitive decline remains controversial. The amyloid hypothesis has been revised recently to include the notions that smaller soluble A␤ oligomers may play an early and significant role in AD and correlate with the impairment in cognitive function, learning, and memory (Lue et al., 1999; McLean et al., 1999; Lesné et al., 2006 Lesné et al., , 2008 Cheng et al., 2007; Selkoe, 2008) . In this regard, we found no significant variation in A␤ deposits despite an early aggravation of memory impairment in APP Swe /PS1/ CCR2 Ϫ/Ϫ . Cognitive impairment occurs at 3 months of age when there are only few scattered plaques. By contrast, brain levels of soluble intracellular A␤ species are drastically increased at this age, suggesting a rapid accumulation of A␤ species within neurons. The significant correlation between cognitive deficit and intracellular A␤ levels supports the hypothesis that intracellular A␤ impairs neuronal functions (Wirths et al., 2004; LaFerla et al., 2007) . These data confirm previous studies showing intraneuronal A␤ accumulation in different mouse models of AD (Billings et al., 2005; Cruz et al., 2006; Oakley et al., 2006; Knobloch et al., 2007) and in postmortem brain tissues from AD patients (Gouras et al., 2000 (Gouras et al., , 2005 . Intracellular A␤ species may therefore be responsible for the early AD-related cognitive deficits before A␤ plaque formation. 
APP Swe /PS1/CCR2
Ϫ/Ϫ mice exhibited increased intracellular levels of all A␤ species, suggesting the increase of A␤ production in their brain. In addition, inhibition of A␤ degradation could also participate in A␤ accumulation in the brain, since the expression of neprilysin/Mme, a major A␤-degrading enzyme, is decreased in a context of CCR2 deficiency (El Khoury et al., 2007) . Moreover, synaptic activity can reduce intraneuronal A␤ by Mme action and protect against A␤-related synaptic alterations (Tampellini et al., 2009) . In this regard, the expression of synaptic genes (e.g., EGR1, PSD95, and NR2A) is downregulated in the brain of 3-monthold APP Swe /PS1/CCR2 Ϫ/Ϫ mice (data not shown). Since A␤ can be phagocytosed by microglia (Mandrekar et al., 2009 ) and astrocytes (Matsunaga et al., 2003; Nielsen et al., 2009 ), CCR2 deficiency can also affect A␤ clearance by preventing the recruitment of CCR2 ϩ monocytes and contributing therefore to soluble A␤ accumulation. Such a mechanism is supported by the soluble extracellular A␤ levels (including 12-, 6-, 2-, and 1-mers), which were significantly higher in the brain of APP Swe /PS1/CCR2 Ϫ/Ϫ mice.
Many soluble A␤ assemblies have been shown to induce cognitive impairment, such as extracellular A␤*56 (Lesné et al., 2006) or soluble A␤ dimer and trimer (Cleary et al., 2005) . Moreover, Mme overexpression fails to prevent learning and memory deficits despite restricting A␤ deposition in cortex and hippocampus. Interestingly, soluble A␤ trimers and A␤*56 levels were not reduced in the brain of these APP mice (Meilandt et al., 2009) . In the Tg2576 model, memory impairment begins when A␤ dimers start to accumulate (i.e., ϳ6 months before plaque formation) (Kawarabayashi et al., 2004) . In AD patients, soluble intracellular and membrane-associated A␤ in temporal neocortex is more closely related to AD symptoms than other A␤ species (Steinerman et al., 2008) . A␤ binding to cell membranes is therefore not negligible and could disrupt their fluidity and, therefore, synaptic activity and neurotransmission. Another important aspect of the amyloid cascade is that extracellular-, intracellular-, and membrane-associated pools of A␤ are tightly interconnected. For example, extracellular A␤ can increase its own production and then induce A␤ accumulation within neurons (Peters et al., 2009; Tampellini et al., 2009) . Moreover, animals with amyloid plaques have normal memory function throughout an episode of reduced extracellular A␤ oligomers (including A␤*56), which occurs during a period of accelerated amyloid plaque formation (Lesné et al., 2008) . These data strongly suggest that the A␤ entities responsible for memory decline and disruption of synaptic plasticity in AD pathology are variable, but always associated to soluble fractions. Our study further reinforces this concept, be- cause soluble A␤ accumulation occurs before plaque formation in cognitively impaired young CCR2-deficient mice.
We expected to find a lower number of plaque-associated microglia in CCR2-deficent mice because of the inability of CX 3 CR1 lo CCR2 ϩ GR1 ϩ monocytes to infiltrate the brain despite enhanced MCP-1 gene expression in AD mouse models (Simard et al., 2006; El Khoury et al., 2007) . Surprisingly, we found more microglia recruited around A␤ plaques in APP Swe /PS1/CCR2 Ϫ/Ϫ mice than APP Swe /PS1. Microglia are known to react quickly to A␤ production and subsequently migrate toward plaques (Bolmont et al., 2008) . Despite similar A␤ deposits, microglia recruitment was enhanced in APP Swe /PS1/CCR2 Ϫ/Ϫ mice from 6 months of age, suggesting a compensatory mechanism induced by the lack of CCR2-expressing cells. As CCR2
Ϫ/Ϫ cells cannot migrate in response to MCP-1 (El Khoury et al., 2007) , the chemokine responsible for this strengthened attraction has yet to be identified. These plaque-associated microglia expressed strongly TGF-␤1 and TGF-␤1 receptor-R1 and -R2 transcripts, which were increased in the brain of APP Swe /PS1/CCR2 Ϫ/Ϫ mice. Enhanced TGF-␤1 levels have already been described in AD patients (van der Wal et al., 1993; Wyss-Coray et al., 1997; Rota et al., 2006) and in our mouse model of AD (Richard et al., 2008) . Although the role of TGF-␤1 in AD pathology remains controversial, this cytokine binds A␤ with high affinity and enhances its oligomerization in vitro (Mousseau et al., 2003) . Moreover, TGF-␤1 overexpression accelerates and promotes amyloidogenesis in AD mice (Wyss-Coray et al., 1997 . Interruption of TGF-␤1 signaling in bone marrow-derived microglia/macrophages mitigates cognitive impairment and attenuates amyloidosis in AD mice (Town et al., 2008) . Indeed, macrophage lacking TGF-␤1 signaling phagocyte A␤ monomers and oligomers. By contrast, TGF-␤1 in brain dampens microglial activation (Brionne et al., 2003) . This effect of TGF-␤1 could suppress the ability of macrophage/microglia to eliminate or restrict soluble A␤ oligomers and consequently aggravate memory deficits. These results further support previous studies suggesting a detrimental role of TGF-␤ system on cognitive impairment and A␤ accumulation.
Microglia surrounding A␤ plaques also strongly expressed CX 3 CR1 transcripts. CX 3 CR1 expression is enhanced in APP Swe /PS1/CCR2 Ϫ/Ϫ mice, correlating with the degree of microglial recruitment. CX 3 CL1 is primarily produced by neurons and signals via CX 3 CR1 within microglia and macrophages (Harrison et al., 1998; Cardona et al., 2006) . CX 3 CR1 deficiency is neurotoxic in mouse models of Parkinson's disease, amyotrophic lateral sclerosis, and systemic lipopolysaccharide administration, suggesting that CX 3 CL1-CX 3 CR1 signaling in microglia is beneficial to neurons (Cardona et al., 2006) . By contrast, memory impairment and A␤ pathology are worsened in APP Swe /PS1/CCR2 Ϫ/Ϫ mice, a phenomenon associated with increased recruitment of CX 3 CR1-positive microglia and upregulation of CX 3 CR1 transcript levels. These data point toward a detrimental role of CX 3 CR1 in APP Swe / PS1 mice. Indeed, a recent study demonstrated that CX 3 CR1 deficiency prevents neuronal loss in a mouse model of AD (Fuhrmann et al., 2010) . This discrepancy might be explained by a phenotypic change of microglia in a context of CCR2 deficiency. Indeed, the robust expression of TGF-␤1, TGF-␤1 receptors, and CX 3 CR1 in microglia associated to plaques supports the idea that CCR2 deficiency gives rise to a phenotype of alternatively activated microglia (Mosser and Edwards, 2008) , which are apparently unable to counteract AD pathology.
CCR2 is required for monocytes to emigrate from bone marrow (Serbina and Pamer, 2006; Tsou et al., 2007; Engel et al., 2008; Jia et al., 2008) . Adoptive transfer studies with Ly-6C high monocytes have shown that they rapidly return to bone marrow in the absence of active recruitment to inflammatory sites (Varol et al., 2007 (Varol et al., , 2009 ). Therefore, CCR2 deficiency drastically decreases the frequency of monocytes in blood, which could contribute to the detrimental effects of CCR2 deficiency in APP Swe / Ϫ/Ϫ mice (e) (n ϭ 3-5). Such a tendency was validated by measuring the area containing CX 3 CR1-positive message in cortex on dark-field photomicrographs (f). Results are expressed as mean Ϯ SEM; n ϭ 3-4; Student's t test; *p Ͻ 0.05 versus APP Swe /PS1 at same age. Scale bars: a, b, 500 m; c, d, 50 m. PS1. A "peripheral sink hypothesis" exists, based on the findings of active A␤ transport from the CNS into the periphery across the blood-brain barrier via the low-density lipoprotein receptor (Deane et al., 2004) , and from the periphery into CNS via the receptor for advanced glycation end products (Shibata et al., 2000; Deane et al., 2003) . The peripheral sink hypothesis proposes that even low levels of free A␤ in the blood may alter the dynamics of transport and thereby contribute to a net efflux of A␤ from the brain (DeMattos et al., 2001; Holtzman et al., 2002; Lemere et al., 2003) . It would then be possible that CCR2-competent mononuclear cells participate in the clearance of blood A␤ and are part of such a "sink hypothesis" by carrying soluble A␤ species out of the brain.
In conclusion, we demonstrated that CCR2 deficiency in APP Swe /PS1 mice provokes a rapid cognitive decline closely correlated with brain accumulation of soluble A␤ oligomers and a robust mRNA expression of TGF-␤1, TGF-␤-R2, and CX 3 CR1 in microglia. Our study supports a neuroprotective role of CCR2-competent cells in the pathophysiology of AD. We propose that such innate immune mechanisms may be deficient or suboptimal in AD patients and, therefore, that improving the availability of CCR2 ϩ monocytes has considerable therapeutic potential.
